James J. Ferguson, III, MD

Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes (Part I)

08/01/2008

ABSTRACT: Traditional antithrombotic regimens for the management of acute coronary syndromes are far from optimal. There is considerable opportunity for improvement of standard treatment with unfractionated heparin and aspirin. The...

ABSTRACT: Traditional...

08/01/2008

Journal of Invasive Cardiology

Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes (Part II)

08/01/2008

James J. Ferguson III, MD;

Continued from previous page Several other recent studies have also examined the efficacy and safety of the combination of LMWHs and GP IIb/IIIa antagonists in the catheterization laboratory (Table 1). Kereiakes et al. reported the results...

Continued from previous...

08/01/2008

Journal of Invasive Cardiology

Commentary

Of Swiss Alchemists and Road Hazards

08/01/2008

Cindy W. Tom , MD;

James J. Ferguson III, MD;

“Alle Ding’ sind Gift und nichts ohn’ Gift; allein die Dosis macht, dass ein Ding kein Gift ist” [ All things are poison and nothing is without poison; only the dose permits something not to be poison ] – ParacelsusAlthough he was born...

“Alle Ding’ sind Gift und nichts...

08/01/2008

Journal of Invasive Cardiology

Case Report

Direct Stenting and Placement of a Distal Protection Device after Laser Angioplasty in a Saphenous Vein Graft with Severe Stenos

08/01/2008

Shun Kohsaka , MD;

Eduardo Hernandez-Vila , MD;

James J. Ferguson III, MD;

Patients with recurring symptoms of angina due to saphenous vein graft (SVG) disease pose a difficult and increasingly frequent challenge. In general, these patients are older and have more extensive and diffuse disease of both the native...

Patients with recurring symptoms...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Pharmacoinvasive Management of Acute Coronary Syndrome:
Incorporating the 2007 ACC/AHA Guidelines

08/01/2008

Marc S. Cohen , MD;

Jose G. Diez , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

David A. Morrow , MD, MPH;

Every year, more than 1 million patients are admitted to a hospital with a diagnosis of unstable angina or non-ST-elevation myocardial infarction (UA/NSTEMI).1 Relative to acute ST-elevation myocardial infarction (STEMI), patients with...

Every year, more than 1 million...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Strategies for Optimizing Outcomes in the NSTE-ACS Patient: The CATH (Cardiac Catheterization and Antithrombotic Therapy
in th

08/01/2008

Edward T.A. Fry , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

Jacob Shani , MD;

Marc S. Cohen , MD;

Jose G. Diez , MD;

Target Audience: Clinical Cardiologists, Interventional Cardiologists and Nurses. Release Date: 12-01-06 Expiration Date: 11-30-07 Learning Objectives: Upon completion of this educational activity, participants should be able to: Educate...

Target Audience: Clinical...

08/01/2008

Journal of Invasive Cardiology

Continuing Education

Strategies for Optimizing Outcomes in the NSTE-ACS Patient: The CATH (Cardiac Catheterization and Antithrombotic Therapy
in th

08/01/2008

Marc S. Cohen , MD;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

Sunil V. Rao , MD, FACC, FSCAI;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

Jacob Shani , MD;

(PART II) A second group of patients who have received less attention were those who were switched at randomization; approximately three quarters of the patients were on some form of antithrombotic therapy prior to randomization — half of...

(PART II) A second group of...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Over the past decade, impressive reductions in mortality, reinfarction and length of hospital stay have been reported in large-scale studies of patients with acute coronary syndrome (ACS). Despite these advances, substantial challenges remain...

Over the past decade, impressive...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Part II of III - Continued TABLE 3 KEY (continued) 2) Unfractionated heparin(UFH) can be used as an alternative to enoxaparin. If UFH is used in the setting of PCI, activated clotting time (ACT) should be followed to achieve an appropriate...

Part II of III -...

08/01/2008

Journal of Invasive Cardiology

Review

Pharmacoinvasive Management of Acute Coronary Syndrome in the Setting of Percutaneous Coronary Intervention: Evidence-Based, Sit

08/01/2008

James J. Ferguson III, MD;

James P. Zidar , MD;

Glenn N. Levine , MD;

James E. Tcheng , MD;

Deepak L. Bhatt , MD, MPH, FACC, FAHA, FESC, MSCAI;

Gideon Bosker , MD;

Gary L. Schaer , MD, FACC, FSCAI;

Dean J. Kereiakes , MD, FACC, FSCAI;

Jose G. Diez , MD;

Edward T.A. Fry , MD;

A total of 5,225 patients were enrolled in the PARAGON B trial. Among these patients, the type of heparin used was known in 5,200 (99.5%). The median duration of therapy was 72.8 hours for UFH and 79.7 hours for LMWH. LMWH was used in about...

A total of 5,225 patients were...

08/01/2008

Journal of Invasive Cardiology